alexa GM-CSF Ipilimumab combination extends melanoma survival.


Journal of Cancer Science & Therapy

Author(s): No authors listed

Abstract Share this page

Abstract In a phase II trial, combining the granulocyte-macrophage colony-stimulating factor sargramostin and the CTLA-4 inhibitor ipilimumab prolonged survival and caused fewer serious side effects in patients with metastatic melanoma compared with ipilimumab alone. This article was published in Cancer Discov and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version